The assessment of extractable and leachables (E&L) has become a cornerstone of pharmaceutical product safety, yet no unified global standards currently exist to quantify or report E&L from container closure systems. While initially limited to primary packaging, E&L evaluations now encompass secondary packaging, manufacturing equipment, and medical devices. Key milestones include the FDA’s 1999 guidance on container closure systems and more recent frameworks from USP chapters < 1661 >, < 1663 >, and < 1664 >, as well as PQRI recommendations. These guidelines have set the foundation for conducting E&L studies, especially for high-risk dosage forms, and are complemented by the forthcoming ICH Q3E, which aims to standardize E&L considerations across dosage forms. This article outlines a structured procedure for E&L assessments, integrating regulatory expectations with practical insights.
References
[1]
Candau-Chacón, R. and Hughes, P. (2020) Impact of Container Closure on Drug Safety. American Pharmaceutical Review. https://www.americanpharmaceuticalreview.com
[2]
Food and Drug Administration (1999) Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics.
[3]
Ali, M.S., Fatima, T., Mubeen, S.A., Khale, M.A. and Mannan, A. (2017) Recent Advancements in Pharmaceutical Packaging. International Journal of Pharmacy & Pharmaceutical Research, 32, 20-28.
[4]
U.S. Food and Drug Administration (2024) Code of Federal Regulations Title 21, Part 211, Subpart E, §211.94—Drug Product Containers and Closures. https://www.ecfr.gov
[5]
Phadke, R., Mali, R. and Gosar, A. (2019) Extractables and Leachables—Pharmaceutical Review. European Journal of Pharmaceutical and Medical Research, 6, 474-483.
[6]
Product Quality Research Institute (2006) Safety Thresholds and Best Practices for Extractables and Leachables in Orally Inhaled and Nasal Drug Products.
[7]
International Conference on Harmonization (2006) ICH Harmonized Tripartite Guideline: Q3B(R2) Impurities in New Drug Products.
[8]
Chakraborty, A. (2018) A Descriptive Study of the Regulations of Leachable and Extractables of US, Europe and Canada. International Journal of Pharmaceutics & Pharmacology, 2, 1-15. https://doi.org/10.31531/2581-3080.1000129
[9]
Broschard, T.H., Glowienke, S., Bruen, U.S., Nagao, L.M., Teasdale, A., Stults, C.L.M., et al. (2016) Assessing Safety of Extractables from Materials and Leachables in Pharmaceuticals and Biologics—Current Challenges and Approaches. Regulatory Toxicology and Pharmacology, 81, 201-211. https://doi.org/10.1016/j.yrtph.2016.08.011
[10]
Jenke, D. (2018) Identification, Analysis and Safety Assessment of Leachables and Extractables. TrAC Trends in Analytical Chemistry, 101, 56-65. https://doi.org/10.1016/j.trac.2017.10.024
[11]
Product Quality Research Institute (2021) Safety Thresholds and Best Demonstrated Practices for Extractables and Leachables in Parenteral Drug Products (Intravenous, Subcutaneous, and Intramuscular).
[12]
Sica, V.P., Krivos, K.L., Kiehl, D.E., Pulliam, C.J., Henry, I.D. and Baker, T.R. (2019) The Role of Mass Spectrometry and Related Techniques in the Analysis of Extractable and Leachable Chemicals. Mass Spectrometry Reviews, 39, 212-226. https://doi.org/10.1002/mas.21591
[13]
Wakankar, A.A., Wang, Y.J., Canova-Davis, E., Ma, S., Schmalzing, D., Grieco, J., et al. (2010) On Developing a Process for Conducting Extractable-Leachable Assessment of Components Used for Storage of Biopharmaceuticals. Journal of Pharmaceutical Sciences, 99, 2209-2218. https://doi.org/10.1002/jps.22012
[14]
Jenke, D. (2007) Evaluation of the Chemical Compatibility of Plastic Contact Materials and Pharmaceutical Products; Safety Considerations Related to Extractables and Leachables. Journal of Pharmaceutical Sciences, 96, 2566-2581. https://doi.org/10.1002/jps.20984
[15]
Cuadros-Rodríguez, L., Lazúen-Muros, M., Ruiz-Samblás, C. and Navas-Iglesias, N. (2020) Leachables from Plastic Materials in Contact with Drugs. State of the Art and Review of Current Analytical Approaches. International Journal of Pharmaceutics, 583, Article ID: 119332. https://doi.org/10.1016/j.ijpharm.2020.119332
[16]
Food and Drug Administration (2005) Guidance for Industry: Nasal Spray and In-halation Solution, Suspension, and Spray Drug Products Chemistry, Manufacturing, and Controls Documentation.
[17]
Food and Drug Administration (2013) Technical Considerations for Pen, Jet, and Related Injectors Intended for Use with Drugs and Biological Products.
[18]
United States Pharmacopeia (2024) General Chapter < 1663 >: Assessment of Extractables Associated with Pharmaceutical Packaging/Delivery Systems. USP Compendium.
[19]
International Pharmaceutical Excipients Council (2021) Guideline for Extractables and Leachables Testing in Packaging Systems.
[20]
Food and Drug Administration (1998) Reviewer Guidance: Nebulizers, Metered Dose Inhalers, Spacers, and Actuators.
[21]
United States Pharmacopeia (2024) General Chapter < 1664 >: Assessment of Leachables Associated with Pharmaceutical Packaging/Delivery Systems.
[22]
International Conference on Harmonization (2003) ICH Harmonized Tripartite Guideline: Q1A(R2) Stability Testing of New Drug Substances and Products.
[23]
United States Pharmacopeia (2024) General Chapter < 661 >: Plastic Packaging Systems and Their Materials of Construction. USP Compendium.
[24]
Jenke, D. (2017) Compatibility of Pharmaceutical Products and Contact Materials: Safety Considerations Associated with Extractables and Leachables. John Wiley & Sons.
[25]
Yao, L. and Zhang, Z. (2020) Advances in Analytical Techniques for Extractables and Leachables in Pharmaceutical Packaging. Journal of Pharmaceutical Sciences, 109, 1234-1245.
[26]
Whelan, S. (2016) The Role of Leachables in Pharmaceutical Quality and Safety. International Journal of Pharmaceutics, 512, 43-51.
[27]
European Medicines Agency (2019) ICH Guideline M7(R1) on Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. https://www.ema.europa.eu
[28]
Food and Drug Administration (2020) FDA Guidance for Industry: Safety Thresh-olds and Best Practices for Extractables and Leachables in Orally Inhaled and Nasal Drug Products. https://www.fda.gov
[29]
Allenspach, C., Brodard, P., Brüderlin, B. and Bühlmann, A. (2019) Advances in Mass Spectrometry for E&L Studies: Combining Sensitivity with Robustness. Journal of Pharmaceutical and Biomedical Analysis, 174, 112-121.
[30]
Hotha, K.K., Reddy, S.P.K., Raju, V.K. and Ravindranath, L.K. (2013) Forced Degradation Studies: Practical Approach—Overview of Regulatory Guidance and Literature for the Drug Products and Drug Substances. International Research Journal of Pharmacy, 4, 78-85. https://doi.org/10.7897/2230-8407.04517
[31]
Gosetti, F., Mazzucco, E., Zampieri, D. and Gennaro, M.C. (2010) Signal Suppression/Enhancement in High-Performance Liquid Chromatography Tandem Mass Spectrometry. Journal of Chromatography A, 1217, 3929-3937.
[32]
European Chemicals Agency (2006) REACH Regulation: A Comprehensive Database for Evaluating Chemical Safety. https://echa.europa.eu
[33]
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (2017) ICH Harmonised Guideline Q3D(R1): Guideline for Elemental Impurities. https://www.ich.org
[34]
Tox21 Program (2018) Toxicology in the 21st Century: Advancing Computational Approaches to Assess Toxicity. https://tox21.gov
[35]
Dennis, R. (2019) Trends in Extractable and Leachable Studies: Implications for Drug Development. Journal of Analytical Chemistry, 93, 1456-1465.
[36]
Jenke, D.R. (2002) Extractables and Leachables in Parenteral and Ophthalmic Drug Products. Pharmacopeial Forum, 28, 1614-1622.
[37]
European Medicines Agency (2022) Guideline on Plastic Immediate Packaging Materials.
[38]
Heller, A. and Pogany, R. (2021) Pharmaceutical Packaging: Ensuring Safety through E&L Studies. Regulatory Affairs Journal, 32, 20-28.
[39]
Kroes, R., Renwick, A.G., Cheeseman, M., Kleiner, J., Mangelsdorf, I., Piersma, A., et al. (2004) Structure-based Thresholds of Toxicological Concern (TTC): Guidance for Application to Substances Present at Low Levels in the Diet. Food and Chemical Toxicology, 42, 65-83. https://doi.org/10.1016/j.fct.2003.08.006
[40]
Ball, D. and Wilkins, S. (2014) The Role of Analytical Method Validation in Ensuring Reliability in Extractables and Leachables Evaluations. PDA Journal of Pharmaceutical Science and Technology, 68, 550-561.
[41]
Food and Drug Administration (2017) Predictive Toxicology Roadmap. https://www.fda.gov/media/109634/download
[42]
Helma, C., Cramer, T., Kramer, S. and De Raedt, L. (2004) Data Mining and Machine Learning Techniques for the Identification of Mutagenicity Inducing Substructures and Structure Activity Relationships of Noncongeneric Compounds. Journal of Chemical Information and Computer Sciences, 44, 1402-1411. https://doi.org/10.1021/ci034254q
